Evidence map›Paper›PMID 39803388›Full record

ArticleEuropean journal of radiology open2025

The predictive power of baseline metabolic and volumetric [

Emil Novruzov, Helena A Peters, Kai Jannusch, Guido Kobbe, Sascha Dietrich, Johannes C Fischer, Jutta Rox, Gerald Antoch, Frederik L Giesel, Christina Antke and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of radiology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Emil NovruzovDepartment of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich Heine University Duesseldorf, Düsseldorf 40225, Germany.
Helena A PetersDepartment of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich Heine University Duesseldorf, Düsseldorf 40225, Germany.
Kai JannuschDepartment of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich Heine University Duesseldorf, Düsseldorf 40225, Germany.
Guido KobbeCenter for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Germany.
Sascha DietrichCenter for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Germany.
Johannes C FischerInstitute for Transplantation Diagnostics and Cellular Therapy, University Hospital Düsseldorf, Düsseldorf, Germany.
Jutta RoxInstitute for Transplantation Diagnostics and Cellular Therapy, University Hospital Düsseldorf, Düsseldorf, Germany.
Gerald AntochDepartment of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich Heine University Duesseldorf, Düsseldorf 40225, Germany.
Frederik L GieselDepartment of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich Heine University Duesseldorf, Düsseldorf 40225, Germany.
Christina AntkeDepartment of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich Heine University Duesseldorf, Düsseldorf 40225, Germany.
Ben-Niklas BaermannDepartment of Hematology, Oncology and Clinical Immunology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf 40225, Germany.
Eduards MamlinsDepartment of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich Heine University Duesseldorf, Düsseldorf 40225, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: [ Materials and methods: Eighteen adult patients were enrolled, who underwent CAR-T-cell therapy accompanied by at least one pretherapeutic and two posttherapeutic [ Results: For early therapy failure, baseline metabolic parameters such as the SUV Conclusion: This study revealed that automated delineation methods of metabolic tumor burden using different thresholds do not differ in outcome substantially. Therefore, the current clinical standard with a fixed absolute threshold value of SUV > 4.0 seems to be a feasible option.

Indexed as

CAR-T-cell therapyFDG PETMetabolic tumor burdenVolumetric PET parameter

Identifiers

PMID39803388
PMCPMC11719856

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.